Cigarette giant Philip Morris International has taken control of Vectura, a UK firm that makes medicine and, of all things, devices to treat respiratory illnesses, after a US$1.1 billion bid. PMI, which manufactures Marlboro and Parliament brand cigarettes, said in a statement on Thursday, September 16, that roughly 75% of Vectura’s shareholders had tendered their support for the deal.
“We are very excited about the role Vectura will play in our Beyond Nicotine strategy,” Jacek Olczak, PMI’s CEO, said. The takeover is part of the cigarette group’s long term strategy to become a “broader healthcare and wellness” company with “smoke-free” products.
Nevertheless, the deal has raised hackles at health groups like the British Lung Foundation, Cancer Research UK, and Asthma UK. Reps have questioned whether it is ethical for a tobacco company to own a company that looks to treat the diseases associated with smoking cigarettes, saying it creates “perverse incentives.”
The two organizations sent a letter of protest to the British government, co-signed by 35 medical professionals and charities. Olczak told The Telegraph last month that critics were “not interested in progress” and simply “settling old scores” with his industry.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
UK Regulator Investigates Tech Giants’ AI Partnerships Amid Competition Concerns
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI